JPWO2023282344A1 - - Google Patents
Info
- Publication number
- JPWO2023282344A1 JPWO2023282344A1 JP2022555690A JP2022555690A JPWO2023282344A1 JP WO2023282344 A1 JPWO2023282344 A1 JP WO2023282344A1 JP 2022555690 A JP2022555690 A JP 2022555690A JP 2022555690 A JP2022555690 A JP 2022555690A JP WO2023282344 A1 JPWO2023282344 A1 JP WO2023282344A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022178039A JP7471613B2 (ja) | 2021-07-08 | 2022-11-07 | 腎毒性軽減剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021113495 | 2021-07-08 | ||
PCT/JP2022/027103 WO2023282344A1 (ja) | 2021-07-08 | 2022-07-08 | 腎毒性軽減剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022178039A Division JP7471613B2 (ja) | 2021-07-08 | 2022-11-07 | 腎毒性軽減剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2023282344A1 true JPWO2023282344A1 (ja) | 2023-01-12 |
JPWO2023282344A5 JPWO2023282344A5 (ja) | 2023-09-19 |
Family
ID=84800740
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022555690A Pending JPWO2023282344A1 (ja) | 2021-07-08 | 2022-07-08 | |
JP2022178039A Active JP7471613B2 (ja) | 2021-07-08 | 2022-11-07 | 腎毒性軽減剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022178039A Active JP7471613B2 (ja) | 2021-07-08 | 2022-11-07 | 腎毒性軽減剤 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4368176A1 (ja) |
JP (2) | JPWO2023282344A1 (ja) |
TW (1) | TW202308664A (ja) |
WO (1) | WO2023282344A1 (ja) |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0506830B1 (en) | 1989-12-20 | 2005-12-14 | Avi Biopharma, Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
EP1191714B1 (en) | 2000-09-22 | 2003-01-29 | Alcatel Alsthom Compagnie Generale D'electricite | Method for monitoring an optical waveguide, monitoring system and monitoring unit for said method |
EP1330520A2 (en) * | 2000-11-02 | 2003-07-30 | Inex Pharmaceuticals Corp. | Therapeutic oligonucleotides of reduced toxicity |
JP2006038608A (ja) | 2004-07-27 | 2006-02-09 | Tokyo Electric Power Co Inc:The | 超音波検査装置及び方法 |
JP2006129594A (ja) | 2004-10-28 | 2006-05-18 | Hitachi Ltd | 船舶用電気推進装置の制御方法及びその装置 |
AU2005306075A1 (en) * | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
LT2024499T (lt) | 2006-05-10 | 2018-02-26 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
CN1868456A (zh) * | 2006-06-25 | 2006-11-29 | 沈阳药科大学 | 反义脱氧寡核苷酸isis23665脂质体制剂及制备方法 |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
NZ599395A (en) | 2008-07-18 | 2013-10-25 | Oncogenex Technologies Inc | Antisense formulation |
JP6478632B2 (ja) | 2011-05-05 | 2019-03-06 | サレプタ セラピューティクス, インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
CN102989007B (zh) * | 2011-06-29 | 2015-12-16 | 湖州市中心医院 | 大规模制备注射用中期因子反义寡核苷酸纳米脂质体的方法 |
KR20220045091A (ko) | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법 |
CN117721110A (zh) | 2011-12-28 | 2024-03-19 | 日本新药株式会社 | 反义核酸 |
AU2014259759B2 (en) | 2013-05-01 | 2020-06-18 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
DK3019200T3 (da) | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
JP6519842B2 (ja) | 2013-10-04 | 2019-05-29 | 国立大学法人神戸大学 | 福山型筋ジストロフィー治療用アンチセンス核酸 |
SG10201811729PA (en) | 2013-12-12 | 2019-02-27 | Life Technologies Corp | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
WO2015105083A1 (ja) | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
KR20240035901A (ko) | 2015-05-19 | 2024-03-18 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
JPWO2017010575A1 (ja) | 2015-07-16 | 2018-04-26 | 協和発酵キリン株式会社 | β2GPI遺伝子発現抑制核酸複合体 |
LT3554554T (lt) | 2016-12-19 | 2022-11-25 | Sarepta Therapeutics, Inc. | Egzoną praleidžiantys oligomero konjugatai nuo raumenų distrofijos |
CA3047010A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
WO2018118599A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
-
2022
- 2022-07-08 EP EP22837758.6A patent/EP4368176A1/en active Pending
- 2022-07-08 WO PCT/JP2022/027103 patent/WO2023282344A1/ja active Application Filing
- 2022-07-08 TW TW111125776A patent/TW202308664A/zh unknown
- 2022-07-08 JP JP2022555690A patent/JPWO2023282344A1/ja active Pending
- 2022-11-07 JP JP2022178039A patent/JP7471613B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP4368176A1 (en) | 2024-05-15 |
JP7471613B2 (ja) | 2024-04-22 |
JP2023130288A (ja) | 2023-09-20 |
TW202308664A (zh) | 2023-03-01 |
WO2023282344A1 (ja) | 2023-01-12 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230627 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240521 |